<code id='7854651B61'></code><style id='7854651B61'></style>
    • <acronym id='7854651B61'></acronym>
      <center id='7854651B61'><center id='7854651B61'><tfoot id='7854651B61'></tfoot></center><abbr id='7854651B61'><dir id='7854651B61'><tfoot id='7854651B61'></tfoot><noframes id='7854651B61'>

    • <optgroup id='7854651B61'><strike id='7854651B61'><sup id='7854651B61'></sup></strike><code id='7854651B61'></code></optgroup>
        1. <b id='7854651B61'><label id='7854651B61'><select id='7854651B61'><dt id='7854651B61'><span id='7854651B61'></span></dt></select></label></b><u id='7854651B61'></u>
          <i id='7854651B61'><strike id='7854651B61'><tt id='7854651B61'><pre id='7854651B61'></pre></tt></strike></i>

          Home / entertainment / leisure time

          leisure time


          leisure time

          author:focus    Page View:368
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In